Alerts will be sent to your verified email
Verify Email
UNICHEMLAB
|
Unichem Laboratories
|
Panacea Biotec
|
Venus Remedies
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
41.0 . | 6.0 . | n/a |
|
Number of ANDA's Approved By USFDA
|
27.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
5.35 % | 9.86 % | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
1.64 % | 37.52 % | 8.87 % |
|
5yr average Equity Multiplier
|
1.32 | 0.36 | 1.32 |
|
5yr Average Asset Turnover Ratio
|
0.47 | 0.41 | 0.96 |
|
5yr Avg Net Profit Margin
|
-1.68 % | 26.1 % | 6.91 % |
|
Price to Book
|
1.12 | 4.11 | 3.92 |
|
P/E
|
12.04 | 0.0 | 25.31 |
|
5yr Avg Cash Conversion Cycle
|
88.84 Days | -170.26 Days | 46.96 Days |
|
Inventory Days
|
151.32 Days | 120.03 Days | 75.64 Days |
|
Days Receivable
|
122.86 Days | 42.2 Days | 54.28 Days |
|
Days Payable
|
205.05 Days | 325.14 Days | 58.86 Days |
|
5yr Average Interest Coverage Ratio
|
2.41 | 2.7 | 396.11 |
|
5yr Avg ROCE
|
1.04 % | -2.79 % | 8.42 % |
|
5yr Avg Operating Profit Margin
|
5.43 % | -3.85 % | 10.14 % |
|
5 yr average Debt to Equity
|
0.11 | -0.69 | 0.08 |
|
5yr CAGR Net Profit
|
32.0 % | -43.68 % | -6.01 % |
|
5yr Average Return on Assets
|
-0.65 % | 9.32 % | 6.69 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
70.22 % | 72.48 % | 41.76 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
19.29 % | -1.11 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.38 % | 0.0 | 0.0 |
|
Unichem Laboratories
|
Panacea Biotec
|
Venus Remedies
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|